论文部分内容阅读
目的评价FEP与FEM两种化疗方案双途径介入治疗原发性肝癌的疗效及安全性。方法95例肝癌,男81例,女14例。年龄32～72岁(中位年龄46岁)。其中FEP组48例、FEM组47例。全部病例均采用动脉灌注及化疗栓塞技术,FEP组选用化疗药物5氟脲嘧啶,表阿霉素、顺铂,FEM组选用5氟脲嘧啶、表阿霉素、丝裂霉素,并联合经皮穿刺无水酒精注射。结果FEP组总有效率54.2%(26/48),中位生存期21.2个月。FEM组总有效率34%(16/47),中位生存期14.6个月。FEP组及FEM组病人1、2、3年生存率分别为89.6%、43.8%、29.2%及85.1%、29.8%、14.9%。FEP组及FEM组病人总有效率、中位生存期及3年生存率经统计学检验具有显著性差异(P<0.05)。结论双途径介入治疗对提高肝癌疗效有重要的临床价值,FEP方案较FEM方案为优。
Objective To evaluate the efficacy and safety of two-way interventional therapy with FEP and FEM in the treatment of primary liver cancer. Methods 95 cases of liver cancer, 81 males and 14 females. Age 32 ~ 72 (median age 46 years). Among them, 48 were in FEP group and 47 in FEM group. In all cases, arterial infusion and chemoembolization were used. FEP group used 5-fluorouracil, epirubicin, cisplatin and 5-fluorouracil, epirubicin, mitomycin, Skin puncture anhydrous alcohol injection. Results The total effective rate in FEP group was 54.2% (26/48) and the median survival time was 21.2 months. The total effective rate in FEM group was 34% (16/47) and the median survival time was 14.6 months. The 1-, 2- and 3-year survival rates of FEP and FEM patients were 89.6%, 43.8%, 29.2% and 85.1%, 29.8% and 14.9%, respectively. The total effective rate, median survival time and 3-year survival rate of patients in FEP group and FEM group were statistically significant (P <0.05). Conclusion The dual-pathway interventional therapy has important clinical value for improving the curative effect of liver cancer. The FEP program is better than the FEM program.